Sometimes, the most expensive mistakes hide in plain sight - or, more accurately, out of sight, behind a freezer door. Ask a study team why biospecimens fail, and you’ll hear about a collection technique or a courier who missed a pickup. Fair. But the quiet failure mode is storage. It’s distributed, assumed, and rarely engineered with the same rigor we give randomization or endpoint analysis. Six months later, storage comes back as assay variability, re‑runs, CAPAs, and a tim

When biospecimen processing fails, it’s not usually the science—it’s the gap between protocol and practice. From centrifuge errors to customs delays, silent pre-analytical variables sabotage the biospecimen lifecycle long before the assay begins. If we don’t build operational readiness into our protocols, even the most promising biomarker study can unravel before the data is even analyzed.

Discover how operationalizing biomarker strategies can transform clinical trial outcomes. From biospecimen logistics to assay readiness, this article explores the critical role of biospecimen professionals in precision medicine. Learn how proactive planning reduces screen failures, accelerates timelines, and improves trial success rates. If you're designing biomarker-driven trials, this is your blueprint for efficient, scalable, and regulation-ready execution.

Rethink the biospecimen lifecycle: plan early, optimize storage, and maximize research impact for precision medicine and biomarker discovery

Traditional biospecimen collection in clinical trials is outdated and burdensome. Explore why change is needed and how patient-centered inn